CytomX Therapeutics, Inc. reported that on May 27, 2025, it regained compliance with Nasdaq's minimum bid price requirement after its stock closed at $1.00 or more for 10 consecutive trading days, resolving the earlier notification of non-compliance dated February 24, 2025.